Research presented at the 62nd Annual ACC Meeting showed that commonly used anti-anginal drugs reduce the number of angina attacks in patients with combined diabetes and are more effective in patients with very poor glycemic control. The FDA approved ranolazine for the treatment of chronic angina pectoris, chest pain, and can be used as a first-line agent for angina pectoris, or if other anti-anginal drugs do not relieve symptoms. However, this randomized, double-blind, controlled trial was the first to evaluate ranolazine in patients with coronary artery disease in combination with angina pectoris with diabetes. Diabetes increases the risk of coronary heart disease, and patients with combined diabetes have more frequent angina attacks than patients with coronary heart disease without diabetes. The TERISA trial included 927 patients randomized to either ranolazine 1000 mg twice a day or a placebo group for 8 weeks. All patients enrolled had stable angina with at least one episode per week and were taking one or two anti-anginal medications. The primary endpoint was the number of self-reported angina episodes from 2 weeks to 8 weeks, which was lower in the ranolazine group than in the placebo group, at 3.8 episodes per week and 4.3 episodes per week, respectively. The secondary important endpoint was the frequency of sublingual nitroglycerin in the same time window, which was 1.7 per week in the ranolazine group and 2.1 per week in the placebo group. Professor Mikhail concluded that angina affects quality of life and increases the risk of hospitalization and health care costs, especially in patients with diabetes. Previous studies have shown that ranolazine reduces the number of angina attacks, and this is the first prospective evaluation of the effect of ranolazine in patients with combined diabetic coronary artery disease. An electronic record book was given to each patient to record the number of angina attacks, sublingual nitroglycerin and other information. The use of the usual recording methods, such as paper recording, may cause bias in the results. This study was designed to increase compliance using electronic recording. 98% of the patients completed the study. Sixty-one percent of the patients were male, 96% had hypertension, 74% had a history of heart attack, 82% were taking statins, and 88% were taking angiotensin inhibitors or angiotensin antagonists. 60% of the patients smoked. Studies have shown that ranolazine is more effective in patients with poor glycemic control, and previous studies have shown that ranolazine lowers oral blood glucose in diabetic patients. Professor Kosiborod believes that ranolazine is an effective anti-anginal drug for patients with coronary artery disease combined with diabetes and may lower blood glucose. If the hypoglycemic effect of ranolazine is established in the future, patients with both angina and diabetes could benefit from it doubly. Subgroup analysis showed no significant difference between the effects of the ranolazine and placebo groups in Russians, Ukrainians and Belarus.